REGULATORY FRAMEWORK FOR DIGITAL TWIN HUMAN BIOLOGY SYSTEMS IN JAPAN

1. INTRODUCTION

Digital Twin Human Biology Systems refer to computational representations of an individual's biological characteristics, physiological processes, organs, tissues and disease conditions. These systems combine medical records, genomic information, laboratory results, wearable-device measurements and artificial intelligence (AI) to simulate biological processes and predict possible health outcomes.

In Japan, digital twins have potential applications in precision medicine, drug development, disease prediction, surgical planning, clinical trials and personalized healthcare. However, their development raises important legal questions concerning medical device approval, personal information protection, informed consent, scientific reliability and liability for inaccurate predictions.

Japan does not currently have one comprehensive statute exclusively regulating human biological digital twins. Instead, their regulation derives from existing medical, pharmaceutical, data protection, research ethics and civil liability legislation.

2. PRINCIPAL LEGAL AND REGULATORY FRAMEWORK

A. Pharmaceuticals and Medical Devices Act (PMD Act)

The PMD Act regulates pharmaceuticals and medical devices, including qualifying medical software.

Where a human digital twin is intended to diagnose, prevent or treat diseases or support regulated medical decisions, it may qualify as Software as a Medical Device (SaMD).

Relevant requirements include:

Applicable marketing approval or certification.

Scientific and clinical performance validation.

Quality management and manufacturing controls.

Risk classification and safety assessment.

Post-marketing safety monitoring.

Appropriate control of software modifications.

The Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) have important regulatory responsibilities.

B. Act on the Protection of Personal Information (APPI)

The APPI governs personal information used in biological digital twin systems.

Genomic information, medical histories and physiological measurements may constitute personal information or personal data depending on their identifiability and statutory classification.

Companies must comply with requirements concerning:

Specifying purposes of utilisation.

Obtaining consent where legally required.

Appropriate third-party data provision.

Security safeguards.

Restrictions on international transfers.

Appropriate handling of sensitive personal information.

C. Medical Practitioners Act

Article 17 restricts the practice of medicine to qualified physicians.

A digital twin platform cannot independently acquire legal authority to diagnose or prescribe treatment merely because its predictions are generated through sophisticated AI technology.

Clinical decisions must remain within applicable professional and medical regulatory requirements.

D. Ethical Guidelines for Medical and Biological Research Involving Human Subjects

These guidelines establish important requirements for human biological research.

They address informed consent, ethical review, research governance, personal information management and appropriate handling of research participants' information.

The August 27, 2026 amendments are scheduled to take effect on December 1, 2026. Therefore, the applicable version must be determined according to the research commencement date.

3. SPECIFIC REGULATORY REQUIREMENTS

A. Biological Data Collection

Digital twin developers must establish lawful procedures for obtaining genomic information, physiological measurements, imaging data and medical records.

B. Informed Consent

Participants should receive understandable explanations concerning data collection, computational simulation, research objectives, secondary use, data sharing and foreseeable risks.

C. Model Validation

Developers should demonstrate that digital representations are sufficiently reliable for their intended applications. Validation should consider population differences, incomplete datasets, model uncertainty and changes in biological conditions.

D. Cybersecurity

Organizations should implement access controls, encryption, authentication, security monitoring and incident-response procedures to protect sensitive biological information.

E. Liability

Where inaccurate simulations contribute to patient injury, liability may arise under Articles 415 and 709 of the Civil Code, depending on contractual obligations, negligence and causation.

4. RELEVANT JAPANESE CASE LAWS

There is no established Japanese Supreme Court judgment specifically concerning human biological digital twin systems. Nevertheless, the following decisions provide relevant analogous legal principles.

1. Jehovah's Witness Blood Transfusion Case – Supreme Court, February 29, 2000 (1998 (O) No. 1081).

Analogous authority.

The Court recognized the importance of respecting patient autonomy and providing explanations necessary for informed medical decisions. Digital twin predictions should not replace meaningful patient consent.

2. Waseda University Personal Information Case – Supreme Court, September 12, 2003 (2002 (Ju) No. 1656).

Direct privacy authority; analogous application to biological data.

The Court recognized that students' names, addresses and other identifying information were legally protected privacy information. The judgment is relevant to unauthorized disclosure of identifiable biological digital twin records.

3. Juki-Net Privacy Case – Supreme Court, March 6, 2008 (2007 (O) No. 403).

Analogous authority.

The Court examined constitutional privacy protection and the management of personal identification information through interconnected databases. Its reasoning is relevant to centralized digital twin databases and information-sharing infrastructure.

4. Kyoto Prefecture Gakuren Case – Supreme Court, December 24, 1969.

Analogous constitutional authority.

The judgment recognized constitutional protection of individual liberties against unjustified public-authority interference. It provides foundational context for privacy protection involving biological information.

5. Kyoto Shimbun Privacy-Related Case – Supreme Court, April 14, 1981 (Kyoto Shi Zenka Shokai Case).

Analogous authority.

This decision is relevant to privacy and personal interests in the context of private-sector information practices. Its principles support careful consideration of the collection and use of personal biological information.

6. Surgical Explanation and Informed Consent Case – Supreme Court, June 19, 1981.

Analogous medical liability authority.

The Court addressed physicians' obligations to explain surgical procedures and associated risks. The principle is relevant where digital twin predictions influence treatment selection or clinical procedures.

These decisions establish general principles rather than direct judicial approval or regulation of digital twin technology.

5. CORPORATE COMPLIANCE AND ENFORCEMENT

Organizations developing human biological digital twins in Japan should:

Establish documented consent and data governance procedures.

Obtain applicable medical device approvals before regulated commercial deployment.

Maintain scientific validation and model-performance records.

Conduct independent ethical review where required.

Establish cybersecurity and data breach response mechanisms.

Maintain human clinical oversight.

Document software modifications and algorithmic changes.

Establish procedures for investigating inaccurate predictions and patient injuries.

Regulatory oversight may involve the MHLW, PMDA, Personal Information Protection Commission and relevant research ethics committees.

6. CONCLUSION

Japan regulates Digital Twin Human Biology Systems through a combination of pharmaceutical and medical device legislation, personal information protection law, medical professional regulation, research ethics requirements and civil liability principles.

The central legal challenge is ensuring that computational representations of human biology remain scientifically reliable, ethically developed and appropriately controlled. Developers cannot avoid responsibility merely by describing their systems as experimental or predictive when they are actually used for regulated medical purposes.

Accordingly, Japan's existing legal framework provides important safeguards for human biological digital twins, although more specific regulatory standards concerning AI-driven biological simulation, continuous model updating, predictive accuracy and individual rights may be required as this technology develops.